Search

Your search keyword '"Yu, Lianbo"' showing total 14 results
Start Over Author "Yu, Lianbo" Journal blood
14 results on '"Yu, Lianbo"'

6. The PKC-β Inhibitor MS-553 Displays Preclinical Efficacy in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia

Author

Gordon, Britten, Muhowski, Elizabeth, Ravikrishnan, Janani, Thangavadivel, Shanmugapriya, Benrashid, Samon, He, Alexander, Misra, Shrilekha, Lai, Tzung-Huei, Marr, Alexander, Yu, Lianbo, Walker, Brandi, Perry, Elizabeth, Grieselhuber, Nicole R., Rogers, Kerry A, Blachly, James S., Kittai, Adam S, Bhat, Seema A, Byrd, John C., Niesman, Michael, Zhang, Kai, Sampath, Deepa, and Woyach, Jennifer A.

Published
2023
Full Text
View/download PDF

7. Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168

Author

Gordon, Britten, Muhowski, Elizabeth, Ravikrishnan, Janani, Benrashid, Samon, Mitchell, Andrew, He, Alexander, Misra, Shrilekha, Lai, Tzung-Huei, Thangavadivel, Shanmugapriya, Marr, Alexander, Yu, Lianbo, Walker, Brandi, Perry, Elizabeth, Rogers, Kerry A, Kittai, Adam S, Bhat, Seema A, Byrd, John C., Sampath, Deepa, Lapalombella, Rosa, Han, Weiguo, Kay, Neil E., Chen, Yi, Tan, Fenlai, Anthony, Stephen P., Chen, Yu, and Woyach, Jennifer A.

Published
2023
Full Text
View/download PDF

8. A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and I n Vi tro Potency in B-Cell Malignancies

Author

El-Gamal, Dalia, primary, Hing, Zachary A., additional, Mitchell, Shaneice, additional, LaFollette, Taylor D., additional, Brennan, Paul J., additional, Flynn, Joseph M., additional, Jones, Jeffrey A., additional, Awan, Farrukh, additional, Andritsos, Leslie A., additional, Blachly, James S., additional, Williams, Katie, additional, Harrington, Bonnie K., additional, Goettl, Virginia M., additional, Woyach, Jennifer A., additional, Lehman, Amy M., additional, Yu, Lianbo, additional, Byrd, John C., additional, and Lapalombella, Rosa, additional

Published
2015
Full Text
View/download PDF

9. The Eµ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing

Author

Rogers, Kerry A., primary, El-Gamal, Dalia, additional, Bonnie, Harrington K., additional, Zachary, Hing A., additional, Virginia, Goettl M., additional, Rose, Mantel, additional, Smith, Lisa L., additional, Yu, Lianbo, additional, Johnson, Amy J., additional, Byrd, John C., additional, Lapalombella, Rosa, additional, and Woyach, Jennifer A., additional

Published
2015
Full Text
View/download PDF

10. Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 thGeneration BTK Inhibitor LP-168

Author

Gordon, Britten, Muhowski, Elizabeth, Ravikrishnan, Janani, Benrashid, Samon, Mitchell, Andrew, He, Alexander, Misra, Shrilekha, Lai, Tzung-Huei, Thangavadivel, Shanmugapriya, Marr, Alexander, Yu, Lianbo, Walker, Brandi, Perry, Elizabeth, Rogers, Kerry A, Kittai, Adam S, Bhat, Seema A, Byrd, John C., Sampath, Deepa, Lapalombella, Rosa, Han, Weiguo, Kay, Neil E., Chen, Yi, Tan, Fenlai, Anthony, Stephen P., Chen, Yu, and Woyach, Jennifer A.

Abstract

Background:Treatment of chronic lymphocytic leukemia (CLL) has been transformed with targeted therapies including inhibitors of Bruton's tyrosine kinase (BTKi). Currently three covalent BTK inhibitors (cBTKi) are approved for CLL, but most patients eventually relapse, commonly through acquisition of the C481S BTK mutation (Woyach et al.2014). Pirtobrutinib and nemtabrutinib are non-covalent BTK inhibitors (ncBTKi) developed to target and inhibit C481S mutant BTK. However novel secondary site mutations in BTK, namely T474I and L528W, have been found to confer resistance to both cBTKi and ncBTKi (Wang et al.2022). Regardless of these mutations, BCR signaling remains intact, suggesting that inhibition of BTK maintains its therapeutic importance. LP-168 is a novel ultra-selective 4 thgeneration BTKi with an active warhead capable of covalent interaction with WT BTK or non-covalent binding when a BTK C481 mutation is present.

Published
2023
Full Text
View/download PDF

14. A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivoand I n Vi troPotency in B-Cell Malignancies

Author

El-Gamal, Dalia, Hing, Zachary A., Mitchell, Shaneice, LaFollette, Taylor D., Brennan, Paul J., Flynn, Joseph M., Jones, Jeffrey A., Awan, Farrukh, Andritsos, Leslie A., Blachly, James S., Williams, Katie, Harrington, Bonnie K., Goettl, Virginia M., Woyach, Jennifer A., Lehman, Amy M., Yu, Lianbo, Byrd, John C., and Lapalombella, Rosa

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results